ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 712

    Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
  • Abstract Number: 713

    Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
  • Abstract Number: 714

    Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • Abstract Number: 715

    Investigating the Role of Vitamin D in Patients with SLE
  • Abstract Number: 716

    Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
  • Abstract Number: 717

    Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study
  • Abstract Number: 718

    Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis
  • Abstract Number: 719

    Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 720

    Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary α1-Microglobulin and Albuminâ�„Creatinine Ratio
  • Abstract Number: 721

    Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
  • Abstract Number: 722

    Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
  • Abstract Number: 723

    Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation
  • Abstract Number: 724

    Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus.  an Observational Cohort Study
  • Abstract Number: 726

    Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 727

    Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids
  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 218
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology